Jun. 24 at 6:41 PM
$BMEA ADA 2026 Poster Highlights (1/3)
ICYMI, data from the Phase II COVALENT-111 study were presented by Juan Pablo Frías, M.D., at the 86th Scientific Sessions of the American Diabetes Association.
Key findings included:
• Durable HbA1c improvements through Week 52, including 40 weeks after treatment discontinuation
• A clinically meaningful 1.8% placebo-adjusted mean HbA1c reduction at Week 52
• Improvements in C-peptide index, supporting enhanced endogenous insulin secretion and restoration of beta cell function
• Generally well tolerated, with no serious adverse events, treatment discontinuations due to adverse events, or new safety signals observed
These findings suggest that icovamenib may provide additive and durable glycemic benefit when used alongside GLP-1 RA-based therapies in patients with inadequately controlled type 2 diabetes and further support its potential as a complementary treatment approach.
Read the full poster here: https://bit.ly/biomea-glycemic-improvements-poster-stocktwits
